Progress of SARS-CoV-2 Main protease peptide-like inhibitors

Chem Biol Drug Des. 2024 Jan;103(1):e14425. doi: 10.1111/cbdd.14425. Epub 2023 Dec 11.

Abstract

The pneumonia outbreak caused by Severe Acute Respiratory Syndrome 2 (SARS-CoV-2) infection poses a serious threat to people worldwide. Although vaccines have been developed, antiviral drugs are still needed to combat SARS-CoV-2 infection due to the high mutability of the virus. SARS-CoV-2 main protein (Mpro ) is a special cysteine protease that is a key enzyme for SARS-CoV-2 replication. It is encoded by peptides and is responsible for processing peptides into functional proteins, making it an important drug target. The paper reviews the structure and peptide-like inhibitors of SARS-CoV-2 Mpro , also the binding mode and structure-activity relationship between the inhibitors and Mpro are introduced in detail. It is hoped that this review can provide ideas and help for the development of anti-coronavirus drugs such as COVID-19, and help to develop broad-spectrum antiviral drug for the treatment of coronavirus diseases as soon as possible.

Keywords: Mpro; SARS-CoV-2; peptide-like inhibitor; structure.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antiviral Agents / chemistry
  • Antiviral Agents / pharmacology
  • Antiviral Agents / therapeutic use
  • COVID-19*
  • Coronavirus 3C Proteases*
  • Humans
  • Molecular Docking Simulation
  • Peptides / pharmacology
  • Protease Inhibitors / metabolism
  • SARS-CoV-2 / metabolism
  • Viral Nonstructural Proteins

Substances

  • 3C-like proteinase, SARS-CoV-2
  • Viral Nonstructural Proteins
  • Antiviral Agents
  • Peptides
  • Protease Inhibitors
  • Coronavirus 3C Proteases